Humans of ICRF: Bonnie Fish

Bonnie is a partner, Director of Legal Research, and Coordinator of Continuing Professional Development at Fogler Rubinoff LLP. Bonnie is also an adjunct Professor at the Faculty of Law, University of Toronto.

Bonnie fell in love with ICRF at the Women of Action Luncheons.  When her dear friend died of stomach cancer at age 53 she knew it was time to get more involved. She currently sits on the executive of ICRF and looks forward to the challenge of being President in December 2018.

ICRF combines two things which are very important to her – the fight to conquer Cancer and Israel.

ICRF Parlour Meeting with Dr. Mark Israel

On June 17th, over 30 people gathered to listen to Dr. Mark Israel: a pediatric oncologist, translational scientist and a nationally recognized leader in cancer research. Dr. Israel is the National Executive Director of ICRF and flew from New York to Toronto to speak to some of our most involved community members about the future of ICRF, cancer research, and the development of new treatments. This summer parlour meeting was a wonderful event full of learning, inspiration, and hope for a better future.

Play video

Israeli Researchers Shrink Cancer Tumors By Manipulating Emotions

Source: nocamels.com

he potential that future cancer treatments could include noninvasive stimulation of the brain is genuine, according to researchers from the Technion – Israel Institute of Technology in Haifa who say they have successfully shrunk cancerous tumors in mice by manipulating the brain’s reward system.

In a study recently published in the journal Nature Communications, the Israeli scientists showed how emotions in the brain can influence the way in which the immune system responds to cancer; how positive emotions and optimistic feelings can have an impact on the growth of cancerous tumors.

Continue reading

Will Israeli researchers cure late-stage cancer?

Source: israelnationalnews.com

While immunotherapy has been around for decades, new advances in the field coupled with recent drug approvals from the US Food & Drug Administration have intensified interest in immunotherapy and its applications for cancer treatment, especially late-stage cancers that resist conventional treatments. Immunotherapy drugs already are helping patients with melanoma, lung, stomach, liver and bladder cancers, as well as some blood cancers.

Continue reading